Reforgene presents novel-target gene editing thalassemia clinical results at EHA 2022
The 27th European Hematology Association Congress (27th EHA Congress) will be held in Vienna, Austria, from June 9 to 17, 2022. Guangzhou Reforgene Medicine Co., Ltd. ("Reforgene"), a leading Chinese gene editing drug company, will publicly report for the first time at the 2022 EHA Congress the preliminary clinical research results of its beta-thalassemia gene editing therapy product RM001.
This is the first globally reported clinical study of thalassemia with gene editing modification of the gamma-globin promoter, and also the first time a Chinese pharmaceutical company has reported thalassemia gene editing clinical results at an international conference and at EHA.
The EHA Congress is one of the largest international conferences in the global hematology field, with more than 10,000 professionals from over 100 countries attending each year to share and discuss the latest scientific and clinical research results in hematology. Considering the COVID-19 pandemic, Reforgene chose to report the preliminary clinical research results of "RM001" in the form of a poster this time, which will present internationally leading safety and efficacy data for the product.
Abstract number: P1465. Title: Initial Safety and Efficacy Study of RM001, Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Transfusion-Dependent Beta-Thalassemia. Time: June 10 (European local time).
About RM001
Thalassemia is the monogenic genetic disease with the widest distribution and largest affected population worldwide, lacking effective curative drugs and with huge unmet clinical needs. RM001 is an autologous hematopoietic stem cell gene editing therapy/product independently developed by Reforgene for the treatment of transfusion-dependent beta-thalassemia. The therapy uses CRISPR/Cas gene editing technology to permanently modify the gamma-globin promoter, activating the body's natural synthesis of fetal hemoglobin (HbF), continuously alleviating the hemolytic anemia symptoms caused by beta-globin deficiency, and achieving the goal of a one-time administration to cure beta-thalassemia.
Reforgene has carried out highly effective clinical research, and all patients smoothly escaped transfusion dependence and were discharged within 1-2 months after cell reinfusion, opening a new chapter of life. At this EHA Congress, we report the clinical observation data of the first two patients, both of whom have been followed up for more than 5 months and are in good condition.
At present, pharmaceutical companies in China, Europe and the United States are all developing curative products based on gene-edited autologous hematopoietic stem cells. The CTX-001 product of CRISPR Therapeutics in the United States, which is in Phase I/II clinical research, indirectly releases gamma-globin by editing the BCL11A erythroid enhancer to suppress BCL11A expression. Reforgene's RM001 instead adopts a novel strategy of directly reactivating gamma-globin gene expression, avoiding editing BCL11A, an important multifunctional transcription factor, and thus has better safety.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.